Stephen P. Mulligan
Affiliations: | Faculty of Medicine and Health | University of Sydney, Camperdown, New South Wales, Australia |
Google:
"Stephen Mulligan"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Fatima N, Shen Y, Crassini K, et al. (2024) The CIpP activator, TR-57, is highly effective as a single agent and in combination with venetoclax against CLL cells . Leukemia & Lymphoma. 1-13 |
| Anderson MA, Bennett R, Badoux X, et al. (2023) Chronic lymphocytic leukaemia Australasian consensus practice statement. Internal Medicine Journal. 53: 1678-1691 |
| Shen Y, Coyle L, Kerridge I, et al. (2021) Second primary malignancies in chronic lymphocytic leukaemia: Skin, solid organ, haematological and Richter's syndrome. Ejhaem. 3: 129-138 |
| Fatima N, Shen Y, Crassini K, et al. (2021) The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL. Ejhaem. 2: 81-93 |
| Almazi JG, Alomari M, Belov L, et al. (2021) Fludarabine nucleoside induces major changes in the p53 interactome in human B-lymphoid cancer cell lines. Nucleosides, Nucleotides & Nucleic Acids. 1-7 |
| Do C, Best OG, Thurgood L, et al. (2021) Insight into del17p low-frequency subclones in chronic lymphocytic leukaemia (CLL): data from the Australasian Leukaemia and Lymphoma Group (ALLG)/CLL Australian Research Consortium (CLLARC) CLL5 trial. British Journal of Haematology. 193: 556-560 |
| Fatima N, Crassini KR, Thurgood L, et al. (2020) Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia. Cancer Drug Resistance (Alhambra, Calif.). 3: 532-549 |
| Shen Y, Crassini K, Fatima N, et al. (2020) IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment. Blood Advances. 4: 5093-5106 |
| Solman IG, Blum LK, Hoh HY, et al. (2020) Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leukemia Research. 97: 106432 |
| Tam CS, Opat S, D'Sa S, et al. (2020) A RANDOMIZED PHASE 3 TRIAL OF ZANUBRUTINIB VERSUS IBRUTINIB IN SYMPTOMATIC WALDENSTRÖM MACROGLOBULINEMIA:THE ASPEN STUDY. Blood |